ArticleFrontiers in pharmacology2026
Will the introduction of β-lactamase inhibitors alter the adverse event profile of parent penicillins antibiotics? a pharmacovigilance study based on amoxicillin-clavulanate and ampicillin-sulbactam.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate whether the introduction of Methods: A disproportionality analysis was conducted using reports from the FDA Adverse Event Reporting System database (2004-2024). The research compared the safety profiles of amoxicillin versus amoxicillin-clavulanate (ACP) and ampicillin versus ampicillin-sulbactam (ASS) by employing multiple statistical methods, including the Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Empirical Bayesian Geometric Mean (EBGM). The signals were considered significant only when meeting multiple algorithm criteria (Reporting Odds Ratio, Proportional Reporting Ratio, Bayesian Confidence Propagation Neural Network, Empirical Bayesian Geometric Mean). Subgroup analyses by age and gender were performed. Results: Analysis of over 200,000 reports revealed distinct AE spectra. ACP demonstrated a significantly stronger association with hepatobiliary disorders (e.g., drug-induced liver injury, ROR 35.41) compared to amoxicillin alone (ROR 4.98). In contrast, amoxicillin monotherapy showed stronger signals for certain immune-mediated skin reactions. For ampicillin, monotherapy was strongly linked to pregnancy/perinatal events, whereas ASS showed higher risks for gastrointestinal disorders (e.g., hemorrhagic enterocolitis), specific skin reactions, and allergic events. Subgroup analyses indicated that hepatobiliary and renal risks with ACP were more prominent in males and the elderly (≥60 years), while severe skin reactions with ampicillin were more frequent in females. Conclusion: The addition of BLIs significantly may modify the AE profiles of parent penicillins, introducing distinct organ-specific risks. These findings underscore the necessity for personalized risk assessment and monitoring in clinical practice, tailored to the specific combination agent and patient demographics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.